Due to PI3K isoform switching, which is commonly observed in cancer, pan-PI3K inhibitors are far more effective at treating tumors than isoform-specific inhibitors, but the undesirable toxicity has presumably prevented any pan-inhibitors from achieving FDA-approval. The gene discussed is PIK3CD; the disease is cancer.